Windtree's direction shifts to full company sale amid partner hunt for cardiogenic shock program

License out/inPhase 2
Windtree's direction shifts to full company sale amid partner hunt for cardiogenic shock program
Preview
Source: FierceBiotech
Even with Windtree Therapeutics' hunt for a life raft, the company has been moving forward with testing istaroxime to improve systolic and diastolic cardiac function.
Windtree Therapeutics is doing everything possible to advance a pipeline of cardiovascular meds, but it’s still not enough. The biotech is now hunting for a buyer of the entire operation rather than just a simple licensing deal.
The company has engaged a financial services firm to explore strategic alternatives with an aim of maximizing shareholder value, according to a Wednesday press release.
Windtree had already been trying to find a partner for its cardiogenic shock program but will now expand those efforts to include a potential acquisition, merger, company sale or other strategic transaction.
Even with the ongoing hunt for a life raft, Windtree has been moving forward with testing istaroxime to improve systolic and diastolic cardiac function. Two weeks ago, the company announced a licensing deal handing over China and Asia-Pacific rights for the med to Lee’s Pharma. This helped secure $138.1 million in future milestone payments.
Istaroxime helped raise blood pressure in a phase 2 trial that read out in April 2022, meeting the main goal. But a nice share bump from the clinical win wasn’t enough to set Windtree up for next development steps in such a tough biotech market. The company began looking for partners to advance beyond the midstage test.
“While there has been positive data and progress, we believe the opportunity is under-recognized and under-valued in the current financial markets, however, it has resulted in in-bound business development interest,” CEO Craig Fraser said in the release. “Given this, the company has engaged a strategic advisor to help coordinate and assess these opportunities with the intent to maximize shareholder value.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-
Targets
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.